NV
Novartis AG Sponsored ADR (NVSN)
BMV
2,677.00
0.00 (0.00%)
Closed
Aug 21, 2026
Day's Range
2,677.002,677.00
52 wk Range
2,206.002,866.83
Financial Statements - NVSN - Novartis AG Sponsored ADR
Revenue
56.67B▼ 93.7%
Net Income
13.96B▼ 93.3%Net Margin 24.6%
EBITDA
23.12B▼ 93.6%
Free Cash Flow
15.24B▼ 93.6%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 56.67B | 897.62B | 46.66B | 43.46B | 43.97B | 49.89B |
| Cost of Goods | 13.69B | 222.61B | 12.47B | 11.58B | 11.73B | 15.12B |
| Gross Profit | 42.97B | 675.01B | 34.18B | 31.87B | 32.23B | 34.77B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 17.64B | 252.40B | 9.76B | 7.94B | 10.05B | 10.15B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -312M | -3.78B | -227M | -195M | 15.26B | 538M |
| Pre Tax Income | 16.35B | 236.72B | 9.12B | 7.17B | 24.53B | 9.87B |
| Income Tax | 2.38B | 29.52B | 551M | 1.12B | 1.62B | 1.80B |
| Net Income | 13.96B | 207.19B | 14.85B | 6.95B | 24.01B | 8.07B |
| EPS Basic | 7.21 | 5.92 | 7.15 | 3.19 | 10.71 | 3.55 |
| EPS Diluted | 7.15 | 5.87 | 7.1 | 3.17 | 10.63 | 3.52 |
| Basic Shares Outstanding | 1.93B | 35.02B | 101.69M | 106.79M | 109.83M | 111.50M |
| Diluted Shares Outstanding | 1.93B | 35.02B | 101.69M | 106.79M | 109.83M | 111.50M |
| Ebit | 17.49B | 254.17B | 9.97B | 7.97B | 25.31B | 10.74B |
| Ebitda | 23.12B | 362.62B | 18.46B | 14.86B | 30.98B | 17.34B |
| Net Income Continuous Operations | 13.96B | 207.19B | 8.57B | 6.04B | 22.90B | 8.07B |
| Minority Interests | 17M | 2M | -4M | 0 | 3M | 1M |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
